Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
Telix has announced its prostate cancer imaging drug Illuccix won't be negatively impacted by proposed changes to the US medicare system.
SFN
0.00%
0.0¢
![](/images/icons/chart-icon.png)
STANFIELD FUNDS MANAGEMENT LIMITED - News & Media
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No News & Media currently available.